Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Average Rating of “Moderate Buy” from Analysts

Cresco Labs Inc. (OTCMKTS:CRLBF) has been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $2.50.

Several equities analysts have recently commented on CRLBF shares. Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a research note on Sunday, November 10th. Finally, Cormark downgraded Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th.

Cresco Labs Stock Up 4.4 %

Cresco Labs stock opened at $0.97 on Tuesday. The company’s 50-day moving average price is $1.12 and its two-hundred day moving average price is $1.46. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. The stock has a market cap of $475.20 million, a P/E ratio of -4.87 and a beta of 1.79. Cresco Labs has a twelve month low of $0.78 and a twelve month high of $2.65.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.